Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML)

Eitemau Tebyg

• Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized, phase 3 IDHentify Trial
  gan: DiNardo, CD, et al.
  Cyhoeddwyd: (2021)
• Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)
  gan: DiNardo, CD, et al.
  Cyhoeddwyd: (2021)
• Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
  gan: Risueño, A, et al.
  Cyhoeddwyd: (2024)
• AML-432 Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, Phase 3 IDHENTIFY Trial
  gan: DiNardo, CD, et al.
  Cyhoeddwyd: (2022)
• A phase 3 study of Enasidenib (ENA) versus conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 (MIDH2) relapsed/refractory acute myeloid leukemia (R/R AML)
  gan: Papayannidis, C, et al.
  Cyhoeddwyd: (2021)